Journal Mobile Options
Table of Contents
Vol. 27, No. 4, 2009
Issue release date: November 2009
Dig Dis 2009;27:555–559

Therapy- and Non-Therapy-Dependent Infectious Complications in Inflammatory Bowel Disease

Epple H.-J.
Medical Clinic I, Gastroenterology, Rheumatology, Infectiology, Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Patients with inflammatory bowel disease (IBD) are susceptible to infections. Results: Independently from immunomodulatory therapy, IBD predisposes to infectious complications. Thus, the incidence of Clostridium difficile infection is increased in IBD patients, and a significant proportion of these patients contracts C. difficile infection outside the hospital and without precedent antibiotic use. Cytomegalovirus infection has been reported in cortico- steroid-naive patients with ulcerative colitis, and infectious gastroenteritis has been linked to initiation and exacerbation of IBD. Finally, in Crohn’s disease there is a substantial risk for abscess formation, and urinary tract infections occur more frequently than in a non-IBD control population. Apart from the disease process itself, factors that predispose to infectious complications in IBD are malnutrition, advanced age, immunosuppressive medications, leukopenia from immunosuppressive medications, and surgery. However, the main risk for infections is clearly related to the use of immunosuppressive agents such as corticosteroids, azathioprine, methotrexate, cyclosporine, and TNF-blocking biologicals. A wide spectrum of infectious complications has been reported in patients treated with these medications, including viral (e.g. CMV, VZV, EBV), bacterial (e.g. Mycobacteria, Listeria, staphylococci), fungal (e.g. Pneumocystis jiroveci, Aspergillus, Candida, Cryptococcus) and protozoal (Toxoplasma) pathogens. The greatest risks obviously relate to the combined use of immunomodulating agents rather than to individual drugs. The risk of infections is also aggravated by an insufficient immunization status as frequently observed in patients with IBD. Conclusion: Physicians treating patients with IBD must be aware of the risk for infectious complications in these patients as well as of strategies to minimize them.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Ekbom A, Helmick CG, Zack M, et al: Survival and causes of death in patients with inflammatory bowel disease: a population-based study. Gastroenterology 1992;103:954–960.
  2. Hutfless SM, Weng X, Liu L, et al: Mortality by medication use among patients with inflammatory bowel disease, 1996–2003. Gastroenterology 2007;133:1779–1786.
  3. Jess T, Loftus EV Jr, Harmsen WS, et al: Survival and cause specific mortality in patients with inflammatory bowel disease: a long-term outcome study in Olmsted County, Minnesota, 1940–2004. Gut 2006;55:1248–1254.
  4. Jess T, Gamborg M, Munkholm P, et al: Overall and cause-specific mortality in ulcerative colitis: meta-analysis of population-based inception cohort studies. Am J Gastroenterol 2007;102:609–617.
  5. Persson PG, Bernell O, Leijonmarck CE, et al: Survival and cause-specific mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology 1996;110:1339–1345.
  6. Winther KV, Jess T, Langholz E, et al: Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County. Gastroenterology 2003;125:1576–1582.
  7. Aberra FN, Lichtenstein GR: Methods to avoid infections in patients with inflammatory bowel disease. Inflamm Bowel Dis 2005;11:685–695.
  8. Hurst RD, Molinari M, Chung TP, et al: Prospective study of the features, indications, and surgical treatment in 513 consecutive patients affected by Crohn’s disease. Surgery 1997;122:661–668.
  9. Keighley MR, Eastwood D, Ambrose NS, et al: Incidence and microbiology of abdominal and pelvic abscess in Crohn’s disease. Gastroenterology 1982;83:1271–1275.
  10. Mir-Madjlessi SH, McHenry MC, Farmer RG: Liver abscess in Crohn’s disease. Report of four cases and review of the literature. Gastroenterology 1986;91:987–993.
  11. Schwartz DA, Wiersema MJ, Dudiak KM, et al: A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn’s perianal fistulas. Gastroenterology 2001;121:1064–1072.
  12. Ben-Ami H, Ginesin Y, Behar DM, et al: Diagnosis and treatment of urinary tract complications in Crohn’s disease: an experience over 15 years. Can J Gastroenterol 2002;16:225–229.
  13. Gruner JS, Sehon JK, Johnson LW: Diagnosis and management of enterovesical fistulas in patients with Crohn’s disease. Am Surg 2002;68:714–719.
  14. Mylonaki M, Langmead L, Pantes A, et al: Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol 2004;16:775–778.
  15. Hermens DJ, Miner PB Jr: Exacerbation of ulcerative colitis. Gastroenterology 1991;101:254–262.
  16. Kochhar R, Ayyagari A, Goenka MK, et al: Role of infectious agents in exacerbations of ulcerative colitis in India. A study of Clostridium difficile. J Clin Gastroenterol 1993;16:26–30.
  17. Weber P, Koch M, Heizmann WR, et al: Microbic superinfection in relapse of inflammatory bowel disease. J Clin Gastroenterol 1992;14:302–308.
  18. Szilagyi A, Gerson M, Mendelson J, et al: Salmonella infections complicating inflammatory bowel disease. J Clin Gastroenterol 1985;7:251–255.
  19. Ruigomez A, Garcia Rodriguez LA, Panes J: Risk of irritable bowel syndrome after an episode of bacterial gastroenteritis in general practice: influence of comorbidities. Clin Gastroenterol Hepatol 2007;5:465–469.
  20. Porter CK, Tribble DR, Aliaga PA, et al: Infectious gastroenteritis and risk of developing inflammatory bowel disease. Gastroenterology 2008;135:781–786.
  21. Meyer AM, Ramzan NN, Loftus EV Jr, et al: The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease. J Clin Gastroenterol 2004;38:772–775.
  22. Issa M, Ananthakrishnan AN, Binion DG: Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis 2008;14:1432–1442.
  23. Issa M, Vijayapal A, Graham MB, et al: Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007;5:345–351.
  24. Ananthakrishnan AN, McGinley EL, Binion DG: Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008;57:205–210.
  25. Toruner M, Loftus EV, Jr., Harmsen WS, et al: Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134:929–936.
  26. Viget N, Vernier-Massouille G, Salmon-Ceron D, et al: Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 2008;57:549– 558.
  27. Wallis RS, Broder MS, Wong JY, et al: Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:1261–1265.
  28. Wallis RS. Anti-tuberculosis treatment and infliximab. Respir Med 2005;99:1620–1622.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50